ClinicalTrials.gg
Active, not recruitingNCT06473779ARRIVALUpdated Oct 13, 2026

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

A Phase 3 interventional study of Tezepelumab and Budesonide/formoterol in Severe Asthma, sponsored by AstraZeneca. Active, not recruiting at 70 sites in 12 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
310
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Enrollment
8th of 28
310 · median 121
Started
2024
the only one that year
Phase 3
16 of 28
4 open now
Registered
22nd of 28
by date
Lead sponsor
16 of 28
AstraZeneca

Among the 28 studies testing tezepelumab in Asthma, this one is the 8th largest by enrollment, is the only one that started in 2024, is one of 16 in phase 3, and was the 22nd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..

Study details include:

  1. The study duration will be up to 72 weeks.
  2. The treatment duration will be up to 68 weeks.
  3. The visit frequency will be once every 4 weeks (Q4W).
Read the detailed description

This is a multicentre, randomised, open-label, parallel-group, phase IIIb study to assess the potential for tezepelumab-treated patients to (1) reduce maintenance therapy without the loss of asthma control at Week 56, among those who demonstrated asthma control or low biomarkers at Week 24, and (2) be in asthma control and have characteristics of clinical remission at Week 24.

Approximately 65 sites in 10 countries will enrol adult and adolescent patients with severe uncontrolled asthma.

The study is divided into 5 phases as described below:

  • Screening/Run-in Phase (from Week -4 until Week 0, up to 4 Weeks)
  • Treatment Induction Phase (Week 0 to Week 4)
  • Treatment Continuation Phase (Week 4 to Week 24)
  • Tezepelumab Treatment With or Without ICS Step-down Therapy Phase (Week 24 to Week 56)
  • Maintenance Phase (Week 56 to Week 72)
03

Conditions studied

  • Severe Asthma

Browse trials for

Keywords

  • Severe Asthma
  • ICS reduction
  • Asthma control
  • Clinical remission
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses for patients who are at or over the age of majority (as per local law). For patients who are less than the age of majority, in addition to providing their informed consent, the patients' legally authorised representative must also provide their informed assent (Appendix A 3).

    Age

  2. Patients must be 12 to 80 years of age inclusive, at the time of signing the ICF.

    Type of Patient and Disease Characteristics

  3. Documented medical record history for at least 12 months prior to Visit 1.
  4. Documented physician-diagnosed severe asthma within 10 years prior to Visit 1 (ie, severe asthma was not diagnosed more than 10 years prior) consisting of any of the following:

    1. > 12% reversibility, OR
    2. Evidence of airflow variability (to show that lung function is altered over time): FEV1 ≥ 400 mL variability over time, OR
    3. Challenge tests that are positive on one of the below:

    (i) Methacholine - PD20 ≤ 8 mg/mL (ii) Mannitol - PD15 15% drop on FEV1 out of dose \< than 635 mg of inhaled mannitol (iii) Exercise - 10% fall of FEV1

  5. ACQ-5 ≥ 1.5 and \< 3.
  6. History of physician-diagnosed asthma that requires continuous treatment with high-dose ICS (as defined by GINA or highest approved dose per posology per country) plus a LABA for at least 6 months prior to Visit 1 (Appendix I). The ICS and LABA can be contained within a combination product or given by separate inhalers.

    Note: Additional maintenance asthma controller medications (eg, LTRAs, tiotropium, cromone, theophylline) are allowed.

  7. Pre-brochodilator FEV1 > 60% predicted and evidence of FEV1 reversibility of > 12% within 6 months prior to screening or at screening. Patients with normal lung function (FEV1 > 80%) need evidence of airflow variability as per inclusion criterion 4.
  8. Documented history of at least one asthma exacerbation requiring OCS bursts or requiring hospitalization within 12 months prior to Visit 1. An asthma exacerbation will be defined as a worsening of asthma symptoms that leads to any of the following:

    1. A temporary bolus/burst of systemic for at least 3 consecutive days to treat symptoms of asthma worsening; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day bolus/burst of systemic corticosteroids
    2. Or, an ER visit (defined as evaluation and treatment for \< 24 hours in ER) due to asthma that required systemic corticosteroids (as per above)
    3. Or, an in-patient hospitalisation (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥ 24 hours).

    Sex and /Barrier Requirements

  9. Male or female.

    Female patients:

    • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of nonchildbearing potential are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy) or who are . Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the induction phase without an alternative medical cause.
    • The following age-specific requirements apply:

      • Women \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and follicle-stimulating hormone levels in the postmenopausal range.
      • Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
      • Adolescents: if patient is female and has reached menarche or has reached Tanner stage 3 breast development (even if not having reached menarche), the patient will be considered a .
  10. WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP patient and that the vasectomised partner has received medical assessment of the surgical success)
    • Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.
    • Cessation of contraception after this point should be discussed with a responsible physician

    Inclusion Criteria 5.1.2 Treatment Induction Phase at Visit 2 (Week 0):

    Before dosing with tezepelumab at Week 0, patients should fulfil the following criteria:

  11. ACQ-5 ≥ 1.5 and \< 3.
  12. Demonstrated proper inhaler technique (patients with improper technique at screening may be trained during screening, but must demonstrate proper technique before enrollment).
  13. No excessive SABA use (should be \< 5 puffs/day) or for patients using SMART therapy outside the US, no excessive use of SYMBICORT (should be ≤ 8 inhalations/day) or for US patients, no excessive use of AIRSUPRA (should be ≤ 12 inhalations/day).

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  1. Any pulmonary disease other than asthma (eg, active lung infection, , bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or pulmonary or systemic diseases, other than asthma, that are associated with elevated peripheral EOS counts (eg, allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the study or the interpretation
    • Impede the patient's ability to complete the entire duration of study.
  3. A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
  4. Current smokers or patients with smoking history ≥ 10 pack-years and patients using vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
  5. History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
  6. Tuberculosis requiring treatment within the 12 months prior to Visit 1.
  7. History of known immunodeficiency disorder including a positive test at Visit 1, or the patient taking antiretroviral medications as determined by medical history and/or patient's verbal report.
  8. Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures requiring general anaesthesia or inpatient status for > 1 day during the conduct of the study.
  9. Evidence of COVID-19 within 4 weeks prior to screening or ongoing clinically significant COVID-19 sequelae.

    Prior/Concomitant Therapy

  10. Receipt of any marketed or biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives (whichever is longest) prior to Visit 1.
  11. OCS-dependent patients (received chronic OCS therapy [prednisone ≥ 5 mg/day or equivalent]) for at least 3 months preceding Visit 1.
  12. Daily use of maintenance for any reason.
  13. Treatment with systemic /immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for OCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
  14. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
  15. Receipt of 30 days prior to the date of Visit 1 and during the study.
  16. Patients that have been treated with bronchial thermoplasty in the last 12 months prior to Visit 1.

    Prior/Concurrent Clinical Study Experience

  17. Known history of sensitivity to any component of the tezepelumab formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  18. History of anaphylaxis or documented immune complex disease (Type III reactions) following any biologic therapy.
  19. Concurrent enrolment in another clinical study involving an IMP.

    Diagnostic Assessments

  20. Any clinically meaningful abnormal finding in physical examination, haematology, clinical chemistry at Visit 1 which, in the opinion of the investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete the entire duration of the study.
  21. Evidence of active liver disease, including jaundice or , ALT, or ALP > 2 times the at Visit 1.
  22. Positive surface antigen, virus antibody serology at screening, or a positive medical history for hepatitis B or C. Patients with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.

    Other Exclusions

  23. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff), or patients employed by or relatives of the employees of the site or AstraZeneca.
  24. Judgement by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
  25. For women only: Pregnant, breastfeeding, or lactating women. A serum β-HCG pregnancy test must be drawn for at the screening visit. If the results of the serum β-HCG cannot be obtained prior to dosing of the IMP, a patient may be enrolled on the basis of a negative urine pregnancy test, though serum β-HCG must still be obtained. If either test is positive, the patient should be excluded. Since urine and serum tests may miss a pregnancy in the first days after conception, relevant menstrual history and sexual history, including methods of , should be considered. Any patient whose menstrual and/or sexual history suggests the possibility of early pregnancy should be excluded.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
310 participants (actual)

Study arms

  • Experimental
    Group 1 - Asthma Control or Low Biomarkers - Step-down of ICS

    Asthma Control or Low Biomarkers - Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2

    Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol · Combination Product: Salbutamol

  • Experimental
    Group 2 - Asthma Control or Low Biomarkers - No Step-down of ICS

    Asthma Control or Low Biomarkers - No Step-down of ICS. Only patients with asthma control or low biomarkers at Week 24 will be randomized into Group 1 or 2

    Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol · Combination Product: Salbutamol

  • Experimental
    Group 3 - No Asthma Control or Low Biomarkers - No Step-down of ICS

    No Asthma Control or Low Biomarkers - No Step-down of ICS

    Combination Product: Tezepelumab · Combination Product: Budesonide/formoterol · Combination Product: Albuterol/budesonide (AIRSUPRA®) · Combination Product: Mannitol

Interventions

  • Combination productTezepelumab

    IMP. Subcutaneous injection. Unit dose strengths 210 mg.

    Also known as: TEZSPIRE®

  • Combination productBudesonide/formoterol

    Drug pages: Budesonide · Formoterol

    AxMP. Oral inhalation. High-dose: 160 μg/4.5 μg per inhalation; Medium and Low-dose: 80 μg/4.5 μg per inhalation

    Also known as: SYMBICORT® pMDI

  • Combination productAlbuterol/budesonide (AIRSUPRA®)

    Drug pages: Albuterol · Budesonide

    AxMP. Oral inhalation. Reliever only. Unit dose strengths 90 μg/80 μg per inhalation In US only.

    Also known as: AIRSUPRA®

  • Combination productMannitol

    NIMP. Oral nebulization. Unit dose strengths: Graduated doses of 0 mg, 5 mg, 10 mg, 20 mg and 40 mg capsules

    Also known as: ARIDOL®

  • Combination productSalbutamol

    AxMP. Used outside the US only. Oral inhalation. Unit dose strengths: 100 μg per inhalation

    Also known as: Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA

06

What researchers measure

Primary outcomes

  1. Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase.

    Proportion of patients who reduced their SYMBICORT® daily maintenance dose without the loss of asthma control at the end of the step-down phase to either: Outside of the US: * Medium-dose maintenance and reliever therapy, or * Low-dose maintenance and reliever therapy, or * SYMBICORT® anti-inflammatory reliever only In the US: * Medium-dose SYMBICORT® and AIRSUPRA®,or * Low-dose SYMBICORT® and AIRSUPRA®, or * AIRSUPRA® only

    Time frame: Week 56

Secondary outcomes

  1. Proportion of patients in asthma control

    Proportion of patients in asthma control at Week24.

    Time frame: Week 24

  2. Proportion of patients with characteristics of clinical remission

    Proportion of patients with characteristics of clinical remission at Week 24

    Time frame: Week 24

  3. Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24

    Proportion of patients in asthma control at Week 56 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 56

  4. Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24

    Proportion of patients in asthma control at Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 72

  5. Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24

    Proportion of patients in asthma control at both Week 56 and Week 72 among those in asthma control at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 56 and Week 72

  6. Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Proportion of patients in asthma control at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Time frame: Week 56

  7. Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Proportion of patients in asthma control at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Time frame: Week 72

  8. Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24

    Proportion of patients in clinical remission at Week 56 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 56

  9. Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24

    Proportion of patients in clinical remission at Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 72

  10. Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24

    Proportion of patients in clinical remission at both Week 56 and Week 72 among those with characteristics of clinical remission at Week 24; summarised separately for patients randomised to ICS step-down and for patients randomised to no step-down of ICS.

    Time frame: Week 56 and Week 72

  11. Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Proportion of patients in clinical remission at Week 56 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Time frame: Week 56

  12. Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Proportion of patients in clinical remission at Week 72 among those who demonstrated neither asthma control nor low biomarkers at Week 24

    Time frame: Week 72

  13. Proportion of patients in complete remission at Week 56

    Proportion of patients in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Week 56

  14. Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56

    Proportion of patients in complete remission at Week 72 among those in complete remission at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Week 72

  15. Change from Week 24 at Week 56 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)

    Change from Week 24 at Week 56 in: * Mean monthly maintenance ICS dose * Mean monthly rescue ICS dose * Mean monthly total ICS dose (maintenance and rescue doses)

    Time frame: From Week 24 at Week 56

  16. Change from Week 24 at Week 72 in: ° Mean monthly maintenance ICS dose ° Mean monthly rescue ICS dose ° Mean monthly total ICS dose (maintenance and rescue doses)

    Change from Week 24 at Week 72 in: * Mean monthly maintenance ICS dose * Mean monthly rescue ICS dose * Mean monthly total ICS dose (maintenance and rescue doses)

    Time frame: From Week 24 at Week 72

  17. Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56

    Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 56 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 24 and Week 56

  18. Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72

    Cumulative daily ICS dose (maintenance and rescue doses) between Week 56 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 56 and Week 72

  19. Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72

    Cumulative daily ICS dose (maintenance and rescue doses) between Week 24 and Week 72 both summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 24 and Week 72

  20. AAER between Week 0 and Week 24 among all tezepelumab-treated patients

    Annualised Asthma Exacerbation Rate between Week 0 and Week 24 among all tezepelumab-treated patients.

    Time frame: Between Week 0 and Week 24

  21. AAER between Week 24 and Week 56

    Annualised Asthma Exacerbation Rate between Week 24 and Week 56 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 24 and Week 56

  22. AAER between Week 56 and Week 72

    Annualised Asthma Exacerbation Rate between Week 56 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 56 and Week 72

  23. AAER between Week 24 and Week 72

    Annualised Asthma Exacerbation Rate between Week 24 and Week 72 summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Between Week 24 and Week 72

  24. ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients

    ACQ-5 score and changes from baseline at Week 24 among all tezepelumab-treated patients

    Time frame: From baseline at Week 24

  25. ACQ-5 score and changes from Week 24 at Week 56

    ACQ-5 score and changes from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 56

  26. ACQ-5 score and changes from Week 24 at Week 72

    ACQ-5 score and changes from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 72

  27. Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.

    Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from baseline at Week 24 among all tezepelumab-treated patients.

    Time frame: From baseline at Week 24

  28. Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56

    Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 56

  29. Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72

    Proportion of ACQ-5 responders (improvement of≥ 0.5 in ACQ-5 score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 72

  30. SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.

    SGRQ total score and changes from baseline at Week 24 among all tezepelumab-treated patients.

    Time frame: From baseline at Week 24

  31. SGRQ total score and changes from Week 24 at Week 56

    SGRQ total score and changes from Week 24 at Week 56, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 56

  32. SGRQ total score and changes from Week 24 at Week 72

    SGRQ total score and changes from Week 24 at Week 72, summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 72

  33. Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients.

    Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from baseline at Week 24 among all tezepelumab-treated patients

    Time frame: From baseline at Week 24

  34. Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56

    Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 56; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 56

  35. Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72

    Proportion of SGRQ responders (improvement of≥ 4 in SGRQ total score) from Week 24 at Week 72; summarised separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: From Week 24 at Week 72

  36. Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.

    Asthma exacerbations, patient-reported outcomes, and lung function. Pre-BD FEV1 actual values and changes from baseline at Week 24 among all tezepelumab-treated patients.

    Time frame: Baseline at Week 24

  37. Pre-BD FEV1 total score and changes from Week 24 at Week 56

    Pre-BD FEV1 total score and changes from Week 24 at Week 56, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.

    Time frame: From Week 24 at Week 56

  38. Pre-BD FEV1 total score and changes from Week 24 at Week 72

    Pre-BD FEV1 total score and changes from Week 24 at Week 72, summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24 among all tezepelumab-treated patients.

    Time frame: From Week 24 at Week 72

  39. Proportion of pre-BD FEV1 responders from baseline at Week 24

    Proportion of pre-BD FEV1 responders from baseline (defined as patients who achieve either a≥ 5% or ≥ 100 mL improvement from baseline) at Week 24, for all tezepelumab-treated patients

    Time frame: Week 24

  40. Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24

    Proportion of pre-BD FEV1 responders at Week 56 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Week 56

  41. Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24

    . Proportion of pre-BD FEV1 responders at Week 72 among those who were pre-BDFEV1 responders at Week 24; summarized separately for patients randomised to ICS step-down, randomised to no ICS step-down, and those who demonstrated neither asthma control nor low biomarkers at Week 24.

    Time frame: Week 72

07

Study locations

70 sites
  • Research Site
    Palmdale, California 93551, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    Berazategui, 1104, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Concepción del Uruguay, 3260, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Mendoza, M5500CCG, Argentina
  • Research Site
    Quilmes, B1878FNR, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, 2002, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Santa Fe, 3000, Argentina
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Erpent, 5101, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Haskovo, 6300, Bulgaria
  • Research Site
    Pleven, 5804, Bulgaria
  • Research Site
    Razgrad, 7200, Bulgaria
  • Research Site
    Rousse, 7002, Bulgaria
  • Research Site
    Sofia, 1154, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Stara Zagora, 6003, Bulgaria
  • Research Site
    Velika Tarnovo, 5250, Bulgaria
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Windsor, Ontario N8X 1T3, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Regina, Saskatchewan S7N 5A2, Canada
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Svendborg, 5700, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Créteil, 94000, France
  • Research Site
    La Tronche, 38700, France
  • Research Site
    Lyon, 69004, France
  • Research Site
    Marseille, 13915, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Augsburg, 86150, Germany
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Cottbus, 03050, Germany
  • Research Site
    Hanover, 30625, Germany
  • Research Site
    Mainz, 55128, Germany
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Orbassano, 10043, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Chihuahua City, 31200, Mexico
  • Research Site
    Cuauhtémoc, 06700, Mexico
  • Research Site
    Monterrey, 64360, Mexico
  • Research Site
    Badalona(Barcelona), 08916, Spain
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Lugo, 27002, Spain
  • Research Site
    Madrid, 28006, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Belfast, BT9 7BL, United Kingdom
  • Research Site
    Liverpool, L7 8XP, United Kingdom
  • Research Site
    London, SE1 9RT, United Kingdom
  • Research Site
    Southampton, SO16 6YD, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 25, 2024
StartActual
Sep 30, 2024
Primary completionEst.
Jun 25, 2027
CompletionEst.
Jun 25, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
326→310
Oct 6, 2026
Show all 2 updates
  1. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 6, 2026
    Enrollment 326→310
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06473779
Lead sponsor
AstraZeneca
Collaborators
Fortrea
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Sep 30, 2024
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 25, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion